Delhi, July 11, 2024 (GLOBE NEWSWIRE) -- Global mRNA Cancer Vaccines Clinical Trials and Market Future Outlook 2024 Report Highlights:
- mRNA Cancer Vaccines In Clinical Trials: > 60 Vaccines
- Highest Phase Of Clinical Trials: Phase III ( 2 Vaccine)
- mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication and Phase
- First Commercial mRNA Vaccine Approval Expected By 2029
- US and China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 Vaccines
- mRNA Vaccines For Skin Cancer Dominating Trials: > 10 Vaccines
Download Report:
mRNA vaccines have emerged as a novel and promising immunotherapy method for cancer treatment, providing a unique way to use the body’s immune system to combat cancer. Unlike traditional vaccines, which use weakened or inactivated viruses, mRNA vaccines function by sending genetic instructions to the body’s cells, allowing them to make specific proteins that can elicit an immune response. Even though no mRNA vaccines are currently approved for cancer treatment, the industry has enormous potential for growth and revenue generation, making it a lucrative avenue for research and development.
mRNA cancer vaccines work by introducing synthetic mRNA molecules that encode tumor associated antigens (TAAs) into the body’s cells, which then translate the mRNA into corresponding TAAs that are exposed on the cell surface. This prompts the immune system to recognize them as foreign, activating cytotoxic T lymphocytes and other immune cells to target and destroy cancer cells expressing these antigens, leading to a robust and specific anti-tumor response.
Immunotherapies, such as immune checkpoint inhibiters and CAR-T cell therapy, have transformed cancer treatment. While these therapies have shown remarkable success, they can be complex and are often associated with severe side effects. In contrast, mRNA vaccines are simpler and faster to produce. They can be tailored to individual patients’ tumors, providing a personalized approach to treatment. Additionally, mRNA vaccines have shown a favorable safety profile in early trials, with manageable side effects compared to some other immunotherapies.
Traditional cancer vaccines, such as peptide vaccines, use specific peptides to elicit an immune response. Peptide vaccines have led the cancer vaccine landscape for years, showing promise in treating various cancers. However, they have limitations, including limited immune response and the need for adjuvants to boost efficacy. mRNA vaccines, on the other hand, offer several advantages. They can encode multiple antigens, enhancing he breadth of the immune response. Moreover, mRNA vaccines can induce both humoral and cellular immunity, providing a more comprehensive anti-tumor effect. The flexibility and rapid production of mRNA vaccines also make them well-suited for quickly addressing emerging cancer mutations.
The COVID-19 pandemic has had a significant impact on the development of mRNA vaccine technology, as proven by the successful rollout of mRNA-based COVID-19 vaccinations. This achievement not only showed the safety and usefulness of mRNA platforms, but also paved the path for their use in other therapeutic fields, including as cancer immunotherapy. Despite their intriguing potential, no mRNA cancer vaccines have been authorized for clinical use. However, multiple possibilities are currently in clinical studies, with Moderna and Merck’s mRNA vaccine candidate mRNA-4157 for solid malignancies being the most advanced in Phase 3 trials in combination with the PD-1 inhibitor Pembrolizumab. As a result, it is expected to be the first mRNA cancer vaccine to reach the market.
The anticipated first approval of an mRNA cancer vaccine is projected to result in significant sales revenue, with estimates putting initial yearly revenues at approximately US$ 100 million for the pioneer product. As more mRNA cancer vaccines receive regulatory approval, the market value of this segment is expected to exceed US$ 1 billion after two or three additional approvals. Furthermore, cumulative sales of the mRNA cancer vaccine are predicted to reach US$ 5 billion during the first five years of commercialization, demonstrating the significant market potential and unmet medical need addressed by these innovative immunotherapies.
While mRNA vaccines for cancer are still in their early phases, the success of COVID-19 mRNA vaccines and ongoing clinical studies has instilled optimism and excitement in the scientific community. As researchers continue to refine delivery methods, optimize antigen selection, and explore combination strategies with other immunotherapies, mRNA vaccines may become cornerstone of cancer treatment, offering patients a personalized, targeted and potentially more effective approach to combating this formidable disease.
